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• Cholesteryl ester storage disease (CESD) is an
underdiagnosed, autosomal recessive, progressive,
metabolic liver disease due to the deficient activity of
lysosomal acid lipase (LAL)
•  LAL deficiency results in cholesteryl ester (CE)Summary
Cholesteryl ester storage disease (CESD) is caused by deﬁcient
lysosomal acid lipase (LAL) activity, predominantly resulting in
cholesteryl ester (CE) accumulation, particularly in the liver,
spleen, andmacrophages throughout the body. The disease is char-
acterized bymicrovesicular steatosis leading to liver failure, accel-
erated atherosclerosis and premature demise. Although CESD is
rare, it is likely that many patients are unrecognized or misdiag-
nosed. Here, the ﬁndings in 135 CESD patients described in the lit-
erature are reviewed. Diagnoses were based on liver biopsies, LAL
deﬁciency and/or LAL gene (LIPA) mutations. Hepatomegaly was
present in 99.3% of patients; 74% also had splenomegaly. When
reported, most patients had elevated serum total cholesterol,
LDL-cholesterol, triglycerides, and transaminases (AST, ALT, or
both), while HDL-cholesterol was decreased. All 112 liver biopsied
patientshad thecharacteristicpathology,which isprogressive, and
includes microvesicular steatosis, which leads to ﬁbrosis, micro-
nodular cirrhosis, and ultimately to liver failure. Pathognomonic
birefringent CE crystals or their remnant clefts were observed in
hepatic cells. Extrahepatic manifestations included portal hyper-
tension, esophageal varices, and accelerated atherosclerosis. Liver
failure in17 reportedpatients resulted in liver transplantationand/Journal of Hepatology 20
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CE, cholesteryl ester.or death. Genotyping identiﬁed 31 LIPA mutations in 55 patients;
61% of mutations were the common exon 8 splice-junction muta-
tion (E8SJM1G>A), for which 18 patients were homozygous. Geno-
type/phenotype correlations were limited; however, E8SJM1G>A
homozygotes typically had early-onset, slowly progressive dis-
ease. Supportive treatment included cholestyramine, statins, and,
ultimately, liver transplantation. Recombinant LAL replacement
was shown to be effective in animal models, and recently, a phase
I/II clinical trial demonstrated its safety and indicated its potential
metabolic efﬁcacy.
 2013 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.and triglyceride storage, primarily in hepatocytes and
macrophages, leading to hepatomegaly, microvesicular
steatosis, cirrhosis, dyslipidemia, accelerated 
atherosclerosis, and early demise 
• Onset of the clinical manifestations can present from
the first year of life and into adulthood 
• On liver biopsy, the microvesicular steatosis may be
misdiagnosed as NASH, NAFLD, or cryptogenic liver
disease. The histologic diagnosis of CESD is facilitated
by immunostaining for the lysosomal protein, cathepsin
D, which is routinely performed in many pathology
laboratories
• Treatment with statins does not reverse the disease
manifestations, which lead to liver failure. A phase
II clinical trial of enzyme replacement therapy 
indicated the potential safety and effectiveness of this
therapeutic approach
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Fig. 1. Liver histopathology and ultrastructural ﬁndings in CESD. (A and B)
Parafﬁn sections stained with H&E showing uniform microvesicular steatosis in
both (A) early and (B) later stages of CESD. Note the number of foammacrophages
inﬁltrating ﬁbrous septa dividing the liver parenchyma in B. Bar in A represents
50 lm, bar in B 100 lm. (C and D) Immunostaining for both membranous
(LAMP2) and luminal (cathepsin D) lysosomal markers in parafﬁn sections
conﬁrms lysosomal nature of lipid vacuoles in hepatocytes in CESD. (C) Signal for
LAMP2 showing uniformly expanded and activated lysosomal system in both
hepatocytes and macrophages. LAMP2 is in close contact with lipid droplets,
clearly surrounding larger vacuoles. (D) Comparable results achieved with
antibody against cathepsin D. Bars represent 25 lm. (E) Cathepsin D immuno-
staining in primarily non-lysosomal liver steatosis (b-oxidation deﬁciency). The
signal for cathepsin D is discrete and restricted to the peribiliary region leaving
cytosolic lipid vacuoles free. Bar represents 25 lm. (F) Electron micrograph
demonstrating membrane-bound lipid vacuoles and needle-shaped CE crystals in
the cytoplasm of hepatocytes from a 9-year old female with CESD. Magniﬁcation
10,000.
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Introduction
Cholesteryl ester storage disease (CESD; MIM 278000) is an auto-
somal recessive lysosomal storage disorder caused by mutations
in the lysosomal acid lipase gene (LIPA) thatmarkedly reduce lyso-
somal acid lipase activity (LAL; cholesterol ester hydrolase, EC
3.1.13) [1–4]. Deﬁcient LAL activity results in progressive lyso-
somal accumulation of cholesteryl esters (CE), and to a lesser
extent, triglycerides, predominantly in hepatocytes, adrenal
glands, intestines, and cells of the macrophage-monocyte system
throughout the body. The involvement of tissues closely correlates
with their relative participation in receptor-mediated endocytosis
and lysosomal degradation of lipoproteins [2–6]. Clinically, LAL
deﬁciency results in two major phenotypes: infantile-onset Wol-
man disease (WD) (MIM 278000) and later-onset CESD, which
were ﬁrst described in 1956 [7,8] and in 1963 [9], respectively.
WD is a rare, neonatal-onset, fulminant subtype with absent
or less than 1% of normal LAL activity, resulting in massive lyso-
somal accumulation of CEs and triglycerides, predominantly in
the liver, spleen, adrenals, bone marrow, lymph nodes, and in
macrophages throughout the body, particularly in the intestinal
villi. Affected infants present by two to four months of age with
vomiting and diarrhea, and massive hepatosplenomegaly. About
50% have adrenal calciﬁcations. Feeding difﬁculties and malab-
sorption lead to malnutrition, growth retardation, cachexia,
which together with the severe liver disease, contribute to
demise in the ﬁrst three to 12 months of life [2,3,10,11].
In contrast, CESD is an often unrecognized, later-onset subtype
thatmaypresent in infancy, childhood, or adulthood, dependingon
the residual in vitro LAL activity, which typically ranges from 1% to
12% of normal [2,3,12,13]. The progressive lysosomal CE and tri-
glyceride accumulation leads to the characteristic liver pathology,
elevated serum transaminases, and elevated serum LDL-choles-
terol and triglycerides, with normal to low HDL-cholesterol con-
centrations (type IIb hyperlipoproteinemia). Premature demise is
due to liver failure and/or accelerated atherosclerotic disease sec-
ondary to the chronic hyperlipidemia [14,15].
There is a clinical spectrum for CESD with some patients diag-
nosed in childhood, while others remain undiagnosed until adult-
hood. Severely affected patients may present in infancy with
Wolman-like manifestations, such as diarrhea, failure to thrive,
emesis, abdominal distension and even adrenal calciﬁcations,
but survive into childhood or adulthood. Patients typically pres-
ent with hepatomegaly and liver dysfunction or type IIb dyslipro-
teinemia. Hepatomegaly typically leads to a liver biopsy which
grossly appears bright yellow-orange in color, and histologically
is characterized by enlarged lipid-laden hepatocytes and Kupffer
cells, and is characterized as microvesicular steatosis (Fig. 1A and
B) [4,16–18]. The liver biopsy diagnosis may be misclassiﬁed as
non-alcoholic fatty liver disease (NAFLD), non-alcoholic steato-
hepatitis (NASH), or cryptogenic liver disease. The progressive
lipid deposition leads to ﬁbrosis, micronodular cirrhosis, and ulti-
mately to liver failure [4]. Elevation of serum transaminases, ala-
nine aminotransferase (ALT) and/or aspartate aminotransferase
(AST), and hepatomegaly are early indications of liver
impairment.
The LAL enzyme defect results in the reduced hydrolysis of
cholesteryl esters and triglycerides and their massive sequestra-
tion, particularly in the lysosomes of Kupffer cells and hepato-
cytes, as well as other cells of the macrophage/monocyte
system. The lack of free cholesterol due to lysosomal trappingJournal of Hepatology 2013of cholesteryl esters leads to reduced feedback inhibition of 3-
hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase
and increased synthesis of cholesterol, as well as upregulation
of apolipoprotein B (ApoB) synthesis and LDL-receptors on cell
membranes [19–23]. The dysregulated expression of the LDL-
cholesterol-dependent ATP binding cassette transporter 1
(ABCA1) gene contributes to HDL-cholesterol reduction in a man-
ner similar to that in Niemann-Pick type C1 disease [24]. These
metabolic alterations lead to increased serum total- and LDL-cho-
lesterol and triglycerides, and decreased serum HDL-cholesterol,
and the diagnosis of type IIb dyslipidemia [25]. The increased
LDL-cholesterol concentrations cause accelerated atherosclerosis,
and CESD patients have been reported who had premature ath-
erosclerosis, ischemia, strokes, and coronary bypass surgery
[13,15,26–29].
The LIPA cDNA and genomic sequence have been isolated and
characterized [30–33]. The 36 kb gene containing 10 exons is
located on chromosome 10q23.31 and encodes an 2.6 kb mRNA
[31,33,34]. The mature lysosomal enzyme has 399 amino acids.
Although the human enzyme has not been crystallized, its
three-dimensional structure has been predicted based on homol-
ogy with human gastric lipase [35]. To date, over 40 LIPA muta-
tions causing CESD and WD have been identiﬁed [36] (Fig. 2).vol. 58 j 1230–1243 1231
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Fig. 2. LIPA gene mutations in patients with CESD and WD. Note that all mutation nomenclature is based on the cDNA with the A of the initiation sequence ATG as
nucleotide 1. Thus, many of the previously reported mutations have been redesignated by adding the 21 bases in the leader sequence (e.g., H108P to H129P). Note, CESD
mutations in bold are those in the reported patients described here.
Table 1. Characteristics of reported CESD patients.
All reported patients, n (%): 135 (100)
Male 56 (45)
Ethnicity/country of origin, n (%): 
Caucasian/Europe 85 (65)
Caucasian/North American 23 (17)
Caucasian/Latin American 14 (10)
Caucasian/Middle Eastern 4 (3)
Asian 4 (3)
African 1 (0.3)
Age at onset and last report, yr: Onset Last report
Males (n = 56)
Mean 6 17.7
Median 5 13
Range <1-44 1-52
Females (n = 68)
Mean 4 18.49
Median 5 13
Range <1-68 2.2-82
Sex unknown (n = 11)
Mean 5.5 12.95
Median 5.6 12.2
Range 0.1-13 3.3-20.8
Distribution, n (%) 131 (97) 130 (96)
<2 yr 25 (19) 2 (<1)
≥2-5 yr 51 (39) 23 (18)
6-12 yr 33 (25) 32 (25)
13-20 yr 8 (6) 32 (25)
21-40 yr 8 (6) 28 (22)
41-58 yr 5 (4) 12 (9)
>60 yr 1 (<1) 1 (<1)
ReviewCESD is pan-ethnic; however, the disease incidence is
unknown. Prevalence estimates in Europeans have been based
on the fact that a recurrent exon 8 splice-junction mutation, com-
monly referred to as E8SJM (c.894G>A; p.delS275_Q298;
IVS81G>A; hereafter designated E8SJM1G>A; rs 116928232) has
been identiﬁed in patients of European ancestry [2,37,38]
(Fig. 2). Population screening for E8SJM1G>A among healthy
West German individuals indicated a heterozygote frequency of
1 in 200 individuals. Since E8SJM1G>A accounts for about 50–
60% of all CESD mutations, the predicted CESD heterozygote fre-
quency for all LIPA mutations was estimated to be 1 in 100,
indicating a disease incidence of 1 in 40,000 [39,40]. Thus, CESD
may be grossly underdiagnosed, especially in patients of Euro-
pean ancestry.
Therapeutic efforts have included cholestyramine and statins
to decrease cholesterol and ApoB synthesis, and liver transplanta-
tion for liver failure. Preclinical studies of LAL replacement in
human ﬁbroblast cells and murine models demonstrated
‘‘proof-of-concept’’ for enzyme replacement therapy (ERT) [41–
44]. Recently, a phase I/II clinical trial of ERT for CESD indicated
its safety and provided evidence supporting its metabolic effects
[45], stimulating interest in this under-recognized disease.
To date, 135 CESD patients have been described in the litera-
ture, mostly in single case reports or small series of biochemi-
cally, histologically, and/or gene-diagnosed patients. The two
largest series had only seven and 13 patients [46,47]. Therefore,
the clinical, pathologic, biochemical, and molecular genetic ﬁnd-
ings, as well as the natural history and genotype-phenotype cor-
relations in the 97 published reports were reviewed, with the
objective of alerting hepatologists, pathologists, and lipidologists
to this disease, its diagnosis, and current and future treatment.
Literature search and patient demographics
Literature search and data collection
A literature search was undertaken to identify all publications
describing CESD patients in PubMed (http://www.ncbi.nlm.nih.-1232 Journal of Hepatology 2013gov/pubmed) since the original description [9]. Patients diag-
nosed with WD who died in the ﬁrst year of life were excluded.vol. 58 j 1230–1243
Table 2. Method of diagnostic conﬁrmation, serum transaminase activities,
and lipid levels in CESD patients⁄.
Pathologic liver biopsy
Diagnostic confirmation, n (%):
112 (83)
Pathognomonic crystals/clefts 21 (16)
Pathologic LAL activity 114 (84)
LIPA mutation detection:
Patients LIPA genotyped, n (%) 55 (41)
Total mutant alleles detected 106 
Number different mutations 31
E8SJM-1G>A alleles, n (%) 65 (61) 
E8SJM-1G>A homozygotes 17 
Elevated serum transaminase activities:
AST, n 78
n in IU/L (range) 54 (9-5240) 
ALT, n 73
n in IU/L (range) 52 (15-2340) 
Serum lipids in mg/dl, n (range): 
Total cholesterol 110 (104-620)
LDL-cholesterol 43 (119-360) 
HDL-cholesterol 65 (8-50)
Triglycerides 96 (69-425)
⁄Data abstracted from the literature for patients in which the diagnostic methods
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Eighty-two peer-reviewed articles in English and 15 foreign lan-
guage articles were reviewed.
Of the 135 patients, longitudinal data were available for 99
who were followed for two years to >30 years from their initial
diagnoses or symptom onset, including 21 patients who were
described in subsequent reports, providing natural history infor-
mation that could be correlated with their LIPA genotypes when
available. For each patient, the following information was
recorded, if reported: clinical manifestations, age at onset and last
examination, presence and degree of hepatomegaly, and/or
splenomegaly, other organ system involvement, liver pathology,
LAL activity, LIPA mutations, serum total cholesterol, LDL- and
HDL-cholesterol, and triglyceride levels, serum AST and ALT activ-
ities, and treatment including cholestyramine/bile acid seques-
trants, statins, liver transplantation, and age and cause of death.
Patient demographics
Table 1 summarizes the demographic characteristics including
gender, ethnicity, and country of origin, and ages at onset and last
report. Patients were European (65%), North American (17%),
Latin American (10%), Asian from India or Thailand (3%) and Mid-
dle Eastern (3%). There were single case reports of an Australian
and African-American patient [48,49].and serum transaminases and lipids were reported.Clinical manifestations
Age of onset and clinical presentation
Clinical information was reported on all patients, although with
varying detail. The age at earliest symptom onset and/or diagno-
sis was recorded for 131 (97%) patients (Table 1). Median age of
onset for the 56 (45%) males and 68 (55%) females was ﬁve years
for both genders, ranging from birth – 44 years and 1 month-
68 years, respectively. Eleven case reports did not specify gender.
Of these 131 patients, age at onset for 35 (27%) severely affected
children was between birth and two years, 81 (62%) presented
between age 3 and 12 years, and 15 (11%) had onset or diagnosis
during adolescence or as adults. There were ﬁve patients whose
diagnoses were made at autopsy [5,50–52].
Clinically, hepatomegaly presented in 134 (99.3%) patients,
and 74% also had splenomegaly. One mildly affected 27-year
old male had no hepatomegaly, although he had liver pathology
and elevated transaminases [53]. Typically, the patients had
hepatomegaly or hepatosplenomegaly on physical exam or imag-
ing studies when initially evaluated for elevated serum transam-
inase activities or for fever, respiratory infections, and/or other
symptoms [54,55].
Table 2 summarizes the method of diagnosis, including liver
biopsy, LAL activity, and LIPA mutations of genotyped patients,
as well as the serum transaminase activities and lipid levels,
when reported. Elevated AST and/or ALT activities were present
in all cases reporting serum transaminase activities, with signiﬁ-
cant ﬂuctuations at different time points (Table 2). The lipid pro-
ﬁles were not commonly reported for many pediatric patients,
while adult patients often presented with hyperlipidemia that
had variable responses to treatment with statins or cholestyr-
amine. Siblings of affected individuals were diagnosed when ini-
tially symptomatic or pre-symptomatically by LAL assays or LIPA
mutation analyses [26,47,56–58].Journal of Hepatology 2013In general, the more severely affected children were more
readily diagnosed than the CESD patients who had slower pro-
gression of their liver disease, and varying levels of serum lipids
[13,53,59]. Because the diagnosis is challenging, it is likely that
many adult CESD patients are being misclassiﬁed as having
NAFLD, NASH, or cryptogenic liver disease, or remain undiag-
nosed [4,26,60].
Serum cholesterol and triglyceride levels (Table 2)
Total cholesterol was elevated in all 110 patients for whom it was
reported, even though 26% were being treated with HMG-CoA
reductase inhibitors. Of the 43 patients in whom serum LDL-cho-
lesterol was reported, 79% had elevated levels (>200 mg/L), and
over 95% had levels above the normal range, including 49% who
were treated with HMG-CoA reductase inhibitors. There were
65 patients for whom HDL-cholesterol levels were reported,
ranging from 8 to 50 mg/dl; 71% had HDL-cholesterol levels
between 20 and 40 mg/dl, and 18% had levels below 20 mg/dl,
while 11% had levels >40 mg/dl. Interestingly, at least 10 kindred
were reported in which ﬁrst-degree relatives of the probands
who were obligate heterozygotes, as well as heterozygotes
detected by E8SJM1G>A screening, had signiﬁcantly elevated
serum total cholesterol levels [12,13,49,61–71,131]. Several
reports documented the presence of coronary artery disease or
atherosclerosis in the parents of affected patients, though few
heterozygotes had known concomitant liver disease [49,67].Other manifestations
The most common extrahepatic ﬁndings were frequent diarrhea,
abdominal and epigastric pain, emesis, anemia, malabsorption,
cholestasis, steatorrhea, poor growth, gallbladder dysfunction,vol. 58 j 1230–1243 1233
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and cardiovascular disease [72–76,125]. Patients with micronod-
ular cirrhosis had portal hypertension, ascites, cachexia, esopha-
geal varices, gastrointestinal bleeding, and other secondary
complications of liver failure resulting in coma, death or liver
transplantation [51,77]. Esophageal varices were reported in 12
patients, including nine from 5 to 20 years of age [26,46,50,78–
84]. Two cases of hepatocellular carcinoma were reported by
the age of 11 and 52 years [28,85], and adrenal calciﬁcations,
which occur in 50% of patients with WD, were present in nine
CESD patients who ranged in age from <1 to 10 years. Thus, adre-
nal calciﬁcation may occur in either phenotype [52,64,78,84,86–
92]. Gastrointestinal lipid and CE accumulation were a common
ﬁnding, including in the core villi of the lamina propria, lacteal
endothelium, smooth muscle, vascular pericytes, and in the
duodenum and bowel mucosa where foamy macrophages were
present (e.g., [51,93–96]). Cardiovascular manifestations pre-
dominantly involved coronary artery disease, aneurysm and
stroke [6,13,22,26,29].Liver failure and causes of death
Liver dysfunction and/or failure occurred in all 135 patients. Of
the 11 reported deaths, the majority (73%) were due to liver fail-
ure, and progression to esophageal varices was reported in 12
cases. Of the 112 (83%) patients who had liver biopsies, all had
signiﬁcant ﬁndings as described below. Death due to liver disease
progression occurred at 7 to 56 years of age, and 50% of deaths
were in patients under 21 years of age [5,50,52,78]. Only one
reported patient survived beyond 58 years [13], but long-term
follow-up information was not available for most patients. Four,
known additional deaths from liver failure occurred after their
case reports [26,57]; (personal communication Dr. C. Gasche,
Vienna, Austria; Dr. V. McLin, Geneva, Switzerland); (Table 3:
patients 35, 36, 50, and 54).Liver pathology
The massive lysosomal accumulation of CE and triglycerides
leads to a diffuse microvesicular steatosis involving hepatocytes,
Kupffer cells, and macrophages (Fig. 1A and B), which progresses
to ﬁbrosis, and ultimately, to micronodular cirrhosis [4,58,91,97].
Liver biopsy ﬁndings were consistent among patients, and
appeared independent of age, genotype, or other factors. On gross
examination, the liver specimens appeared a striking orange-yel-
low in color. On light microscopy (Fig. 1), the universal ﬁnding
was the diffuse, uniform microvesicular steatosis with minimal
zonal differences within the hepatic lobule [4]. Foamy macro-
phages containing lipid and ceroid were already present in the
sinusoids and portal tracts of young patients. Increased numbers
of storage macrophages and progression to ﬁbrosis were
observed at later stages. In contrast to macrophages, ceroid accu-
mulation did not accompany lysosomal lipid accumulation in
hepatocytes [4].
Microvesicular steatosis is uncommon in other metabolic
causes of liver disease, though rare cases induced by severe mito-
chondrial beta-oxidation-mediated hepatotoxicity, for example
associated with valproic acid use or Reye’s syndrome, have been
reported. Reye’s syndrome has distinctive, mitochondrial
enlargement that can be seen ultrastructurally [98–104].1234 Journal of Hepatology 2013Recently, Hulkova and Elleder re-evaluated a series of 19 CESD
liver biopsies to identify reliable histopathologic criteria that
would distinguish CESD from other forms of microvesicular stea-
tosis, and in particular from NAFLD and other non-lysosomal
fatty liver diseases in children [4]. They found that immunostain-
ing for LAMP1, LAMP2, LIMP2, or with a lysosomal luminal pro-
tein (cathepsin D), readily identiﬁed the lipid accumulation as
lysosomal, facilitating the diagnosis of CESD, abrogating the need
for the ultrastructural demonstration of lysosomal lipid deposi-
tion (Fig. 1C–E). Pathologists should note their speciﬁc methods,
commercial antibody sources, and additional unique histopatho-
logic features of the CESD pathology [4]. Thus, one additional
stain of a parafﬁn section would identify patients for conﬁrma-
tory LAL and/or LIPA gene sequencing.
Pathognomonic birefringent CE crystals were observed in
hepatocytes and/or Kupffer cells in fresh-frozen tissues under
polarized light. In ﬁxed parafﬁn-embedded sections, remnant
clefts were observed where the lipid was extracted during dehy-
drating procedures. These crystals, or their remnant clefts,
observed by electron microscopy were limited by a single lyso-
somal membrane or were free in the cytoplasm. Although only
65 of the 112 biopsies (58%) speciﬁcally described birefringent,
needle-shaped CE crystals, 26 (23%) additional cases reported
CE hepatocyte accumulation, and two reported CE remnant clefts,
thereby accounting for 93 of the 112 cases (or 83%), although CE
crystals presumably would be present in all cases if specimens
were frozen and viewed by polarization microscopy or processed
for electron microscopy.
Of the 112 biopsied patients, 72 (64%) had ﬁbrosis and/or cir-
rhosis, including sinusoidal, portal/periportal or septal ﬁbrosis in
56 (50%), whereas cirrhosis was present in 33 (29%). There were
17 patients (15%) who had both ﬁbrosis and cirrhosis in initial or
subsequent biopsies [105–107]. Some reports did not distinguish
between ﬁbrosis and cirrhosis [58,79,84]. Hepatocyte necrosis
was reported in eight (7%) patients.
Of interest, the microvesicular steatosis and CE accumula-
tion were already present in a prenatally diagnosed fetus at
17 weeks of gestation [89]. The affected fetus was detected in
a family who had a previous child diagnosed at 2 years of
age. The fetal liver had marked membrane-bound CE accumu-
lation in the hepatocytes and syncytiotrophoblasts of the cho-
rionic villi, as well as cholesterol inﬁltration and necrosis of
enlarged adrenal glands. Portal and periportal ﬁbrosis were
observed in the affected two-year old sibling’s liver biopsy,
but not in the fetus, suggesting the progressive nature of
CESD-associated liver disease [89].Diagnosis
The diagnoses of all 135 reported patients were based on deﬁ-
cient LAL activity and/or LIPA gene mutations, or the pathologic
liver biopsy ﬁndings. Markedly deﬁcient LAL activity was demon-
strated in 114 (84%) patients of whom 55 (42%) also had LIPA
gene mutation analyses (Fig. 2). The remaining 21 (16%) patients
were diagnosed by the presence of the pathognomonic CE crys-
tals, or remnant clefts, in their liver biopsies. An affected CESD
fetus was diagnosed prenatally by demonstrating LAL deﬁciency
in cultured amniotic ﬂuid cells [89]. Prenatal diagnosis can also
be reliably made in cultured chorionic villi by LAL assay and/or
by mutation analysis.vol. 58 j 1230–1243
Table 3. Clinical, pathologic, and laboratory data for genotyped CESD patients.
Patient LIPA genotype HGMD LIPA genotype 
(as reported1)
Sex Age at 
onset, yr
Age at last 
report/death, 
yr (cause)
Clinical 
manifestations
Liver/tissue 
pathology
Lab [Ref.]
1 E8SJM-1G>A/E8SJM-1G>A E8SJM-1G>A/E8SJM-1G>A M <5 22 I MVS, BRC IIb [131]
2 E8SJM-1G>A/E8SJM-1G>A E8SJM-1G>A/E8SJM-1G>A M 13 23 SM, GF PBF, BRC, HV IIb, ET [38, 
116]
3 E8SJM-1G>A/E8SJM-1G>A E8SJM-1G>A/E8SJM-1G>A n.r. 3 3 D (fam hx MI 30s + 40s) MVS, BMV IIb, ET [90]
4 E8SJM-1G>A/E8SJM-1G>A E8SJM-1G>A/E8SJM-1G>A F 8 13 HT NB, HS on U/S ET, HC [55, 
113]
5 E8SJM-1G>A/E8SJM-1G>A E8SJM-1G>A/E8SJM-1G>A F <5 41 D, cachexia, malabsorption MVS, F, BRC, 
FC, HL, BP
ET [75]
6 E8SJM-1G>A/E8SJM-1G>A E8SJM-1G>A/E8SJM-1G>A F 0.16 5 FTT, D, AD, SM, PI, HV, KV, F ET, HC, 
HTG
[122]
7 E8SJM-1G>A/E8SJM-1G>A E8SJM-1G>A/E8SJM-1G>A M 6 9 SM PI, HV, KV, F ET, HC [122]
8 E8SJM-1G>A/E8SJM-1G>A E8SJM-1G>A/E8SJM-1G>A (p.S275_
Q298del) + c.894G>A
F 4 10 SM Steatosis, PI, 
F, FC
IIb, ET [113]
9 E8SJM-1G>A/E8SJM-1G>A E8SJM-1G>A/E8SJM-1G>A (p.S275_
Q298del) + c.894G>A
M n.r. 22 SM F, FC IIb, ET [113]
10 E8SJM-1G>A/E8SJM-1G>A E8SJM-1G>A/E8SJM-1G>A (p.S275_
Q298del) + c.894G>A
F 3 3 n.r. NB IIb, ET [113]
11 E8SJM-1G>A/E8SJM-1G>A E8SJM-1G>A/E8SJM-1G>A M 0.8 15 SM NB IIb, ET [117]
12 E8SJM-1G>A/E8SJM-1G>A E8SJM-1G>A/E8SJM-1G>A M 2 18 SM NB IIb, ET [117]
13 E8SJM-1G>A/E8SJM-1G>A E8SJM-1G>A/E8SJM-1G>A F 2 36 SM, ML, I, MLD, ATH, AFIB, 
stroke, GU, ECC, X, CA, FC
HS on U/S, FC, 
BMV
IIb, A, 
ALF 
[29]
14 E8SJM-1G>A/E8SJM-1G>A E8SJM-1G>A/E8SJM-1G>A c.934G>A/
c.934G>A
F 6 24 SM DH IIb [47]
15 E8SJM-1G>A/E8SJM-1G>A E8SJM-1G>A/E8SJM-1G>A c.934G>A/
c.934G>A
F 6 24 HTN DH IIb [47]
16 E8SJM-1G>A/E8SJM-1G>A E8SJM-1G>A/E8SJM-1G>A c.934G>A/
c.934G>A
F 4 22 HTN DH IIb [47]
17 E8SJM-1G>A/E8SJM-1G>A E8SJM-1G>A/E8SJM-1G>A c.934G>A/
c.934G>A
F 5 16 SM, laryngitis DH IIb [47]
18 E8SJM-1G>A/E8SJM-1G>A E8SJM-1G>A/E8SJM-1G>Ac.934G>A/
c.934G>A
Inferred from children’s 
genotypes
F 53 d. 58 (MI) AP, MI DH, BMV HC [47]
19 E8SJM-1G>A/c.594insT E8SJM-1G>A/fsA178X190 M 3 18 GI HV, G, MBL, F, IIb [119]
20 E8SJM/c.980delC E8SJM-1G>A/fs→ 330X M 28 28 SM NB n.r. [90]
21 E8SJM/c.397-398delTC E8SJM-1G>A/fs→137X M 11 22 SM NB n.r. [90]
22 E8SJM-1G>A/c.230ins35/
c.245del14
E8SJM-1G>A/G77fsX82 F 68 d. 82 HF, CA, SM NB n.r. [13]
23 E8SJM-1G>A/c.635delC E8SJM-1G>A/fs→195X
(934G>A)/DC673-5
M 33 d. 52 (liver failure) CA, EA, ATH, aneurysms, 
GA
BRC, C IIb [28, 47]
24 E8SJM-1G>A/R65X E8SJM-1G>A/c.C233T R44→fsX 
(Exon3)
F 11 34 SM, MH DH IIb [47]
25 E8SJM-1G>A/R65X E8SJM-1G>A/c.C233T R44→fsX 
(Exon3)
M 37 49 AP BRC, F, FC, HV, 
DU
IIb, ET [95, 96]
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1Both the HGMD nomenclature and the mutations as described in the original publications are listed. Previously, amino acid substitutions were described as 21 bases
shorter when numbering was based on the peptide post-translational modiﬁcation.
Abbreviations: Clinical manifestations: AC, adrenal calciﬁcations or enlargement; AD, abdominal distension; AP, abdominal pain; ATH, atherosclerosis; CA, cancer; CAD,
coronary artery disease; CF, chronic fatigue; D, diarrhea; ECC, ecchymoses; EV, esophageal varices; FTT, failure to thrive; GA, gonadal atrophy; GF, Growth failure (Ht/Wt
<5th centile); GI, gastrointestinal manifestations; GU, perforated gastric ulcer; HF, heart failure; HT, hypertension; I, icterus; SM, splenomegaly; X, xanthelomatous skin
lesions.
Liver and other tissue pathologies: BP, bowel pathology (bowel bx: mucosal edema, foamy macrophages); FC, foam cells; BMV, bone marrow vacuolization; BRC, birefringent
crystals/clefts (massive); C, cirrhosis, (micronodular cirrhosis); DH, diagnostic hepatopathology; DU, duodenal bx lipid, foam cells; F, ﬁbrosis; G, intracytoplasmic glycogen;
kV, Kupffer cell vacuolization; HL, hepatocyte lipid deposition; HS, hepatic steatosis on ultrasound; HV, hepatocyte vacuolization; KL, Kupffer cell lipid deposition; MBL,
membrane bound lipid; ML, mesenteric lipodystrophy; MLD, metabolic liver disease; MVS, microvesicular steatosis; NB, no biopsy (or not reported); PBF, portal-to-portal
bridging ﬁbrosis; PI, portal inﬂammation; TAO, trabecular architecture obliteration; VL, vacuolated lymphocytes, histiocytes.
Lab ﬁndings: IIb, type IIb hyperlipoproteinemia; A, anemia; ALF, abnormal liver function; HC, high cholesterol; HTG, hypertriglyceridemia; ET, elevated transaminases. n.r.,
not reported.
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Fig. 3. Dried blood spot LAL activity in affected homozygotes, heterozygotes,
and normal individuals. This assay is LAL speciﬁc, as it incorporates a speciﬁc
inhibitor, Lalistat 2, which reduces the activity of the other lipases. LAL activity in
140 normal controls, 11 LAL deﬁcient patients and 15 carriers. Limit of
detection = 0.02 nmol/punch/h. From reference [109], with permission.
JOURNAL OF HEPATOLOGYDeﬁcient LAL activity
LAL activity was determined in cultured ﬁbroblasts, peripheral
leukocytes and liver tissue using various lipase substrates that
were not speciﬁc for LAL, thereby precluding direct comparisons
of the residual LAL activities among patients. The enzyme activi-
ties reported in the 114 patients ranged from ‘undetectable’ to
16% of normal mean values, but were typically between <1%
and 10% of normal mean values for peripheral leukocytes or cul-
tured ﬁbroblasts [13,29,53,62–64,108]. Due to assay variability,
the reported residual enzyme activity did not necessarily predict
disease severity. In contrast, the LAL activities in cultured ﬁbro-
blasts or leukocytes from patients with the more severe LAL deﬁ-
cient subtype, WD, had little, if any, detectable activity [3].
Recently, a LAL-speciﬁc assay was reported which determined
the LAL activity in dried blood spots (DBS) using 4-methylumbel-
liferyl-palmitate as the enzyme substrate, and the LAL-speciﬁc
inhibitor, lalistat 2. This assay resulted in good separation of
the activities for normal controls and CESD homozygotes and het-
erozgyotes [109] (Fig. 3).
LIPA gene mutations
To date, over 40 loss-of-function LIPA mutations have been iden-
tiﬁed in patients with CESD and WD (http://www.hgmd.cf.ac.uk/
ac/index.php) (Fig. 2). Of the 19 known mutations causing WD,
most (37%) are small deletions/insertions, with 26% non-sense,
21% consensus splice-site mutations, 10% missense lesions, and
5% a large deletion. Of the 32 known CESD mutations, mostJournal of Hepatology 2013(50%) were missense, with 25% small deletions/insertions, 16%
non-sense, 6% consensus splice-site mutations, and 3% a large
deletion. The most common mutation, E8SJM1G>A, has been
found only in CESD patients and the two exon 8 splice-junction
variants, E8SJM+1G>A and E8SJM+3C>T, occurred only in WD
patients [3,36]. The common donor-splice-site mutation,
E8SJM1G>A causes alternative splicing leading to the deletion
of exon 8, which encodes a mutant LAL enzyme with no activity,
as well as about 2% to 4% of normally spliced, wild-type mRNA
which encodes 3–8% of normal LAL activity [8,24,37,48]. Non-
sense, small deletions/insertions, splicing, and missense muta-
tions were found in patients with both CESD and WD. However,
the most severe alterations that resulted in markedly reduced
or no LAL activity were detected in patients with WD, while LIPA
mutations that encoded mutant enzymes with residual activity
were found in patients with CESD [110]. Of note, G87V (also
described as G66V) is the LIPA founder mutation for WD among
individuals of Persian Jewish and Bukharin Jewish ancestry, with
an allele frequency of 1 in 32 [88,111].
In vitro LIPA cDNA expression studies have assessed the resid-
ual LAL activity caused by various missense mutations [110].
These studies have shown that the missense mutations associ-
ated with little or no activity, particularly when homozygous,
caused WD. In contrast, missense mutations which encoded
residual enzyme activity (1–5%) in vitro were found in CESD
patients [36,110].
As noted above, most LAL assay methods use different sub-
strates and procedures, are not always LAL-speciﬁc, and there-
fore, are not comparable. For example, the CESD patient with
the highest reported LAL activity (16% of normal mean ﬁbroblast
activity) had severe disease with onset at 6 months of life, hepatic
cirrhosis by 3 years, portal hypertension and esophageal varices
by seven years, and was liver transplanted at 13 years of age
[80,81,112].
Genotype/phenotype correlations
In general, the disease subtype (WD or CESD) and severity are pri-
marily based on the absence or amount of residual LAL activity
determined by the two LIPA mutant alleles. LIPA mutations in
patients with WD primarily result in little or no LAL activity, while
patients with CESD have at least one mutation that results in some
residual enzyme activity. If a patient has the common E8SJM1G>A
allele, or a missense mutation that encodes signiﬁcant residual
enzyme activity, the patient will be protected from having WD
andwill haveCESD, nomatterhowsevere theother allelicmutation.vol. 58 j 1230–1243 1237
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Among CESD patients, who have some residual LAL activity,
the clinical spectrum varies from early onset, rapidly progressive
disease, to a later-diagnosed, more attenuated phenotype. The
CESD severity should reﬂect the LIPA genotype, and the total
residual activity encoded by both alleles. The residual enzymatic
activity will correlate with the disease subtype, age at clinical
onset, and rate of disease progression. The common E8SJM1G>A
and missense mutations, which predict residual LAL activity,
were the most frequent among the genotyped CESD patients.
Of the 135 reported patients, LIPA mutations were identiﬁed
in 55 patients, including four for whom only one mutation was
detected, but whose diagnoses were based on LAL deﬁciency
and/or CE crystals in the liver biopsies. Among these 55 patients,
31 LIPA mutations were identiﬁed including 17 missense, 3 non-
sense, one small insertion, one complex small insertion/deletion,
one double mutation (2 mutations on the same allele), ﬁve small
deletions, one large gene deletion spanning four exons, and two
consensus splice site mutations, including an intronic splice-site
mutation resulting in a deletion of 48 base pairs (exon 7), as well
as the common E8SJM1G>A mutation (Fig. 2, in bold). Six muta-
tions, H295Y, G342R, L200P, R44X, G87V, and E8SJM1G>A have
been identiﬁed in at least two or more unrelated kindred, and
the L179P, 195X (c.673_675delC), and G87V mutations have been
identiﬁed in both CESD and WD patients [56,88,111,132]. Among
the 106 LIPA mutations detected in these 55 patients, the com-
mon E8SJM1G>A allele was present in 61% of mutant alleles,
which included 17 patients who were E8SJM1G>A homozygotes.
One additional patient was inferred to be an E8SJM1G>A homozy-
gote based on molecular testing of the proband’s three children
[47].
To date, there has been no genotype/phenotype correlations
reported for CESD. Such correlations have been limited by the fact
that there are few affected sibs or unrelated affected individuals
with the same genotypes for clinical comparison (Table 3). The
limitations of genotype/phenotype correlations are further high-
lighted by the diversity among the18 E8SJM1G>A homozygotes.
This is the largest group of reported CESD patients with the same
genotype. Almost all E8SJM1G>A homozygotes had onset in the
ﬁrst years of life, followed by progression of their liver disease
into adult life. Of the 15 E8SJM1G>A homozygotes whose ages
of onset were reported, 13 were diagnosed in the ﬁrst year of life
to 6 years of age, and two cases were diagnosed at ages 8 and
13 years. One additional female inferred to be homozygous,
based on her children’s genotypes, who was ﬁrst diagnosed at
53 years of age had a fatal myocardial infarction at 58 years
[47]. Liver disease ﬁndings among the reported E8SJM1G>A
homozygotes ranged from microvesicular steatosis to ﬁbrosis,
and ﬁbrosis with septal bridging, indicative of cirrhosis. Extrahe-
patic involvement among E8SJM1G>A homozygotes included gas-
trointestinal lipid accumulation, severe, acute and chronic
diarrhea, malabsorption, abdominal pain, perforated gastric ulcer,
weight and height below the 5th percentile, anemia, frequent
hospitalizations for respiratory infections, coronary artery dis-
ease including atherosclerosis, heart failure, aortic calciﬁcations,
myocardial infarction, and stroke. While disease progression in
some patients was rapid, in others the progression was slow,
although ultimately leading to hepatic ﬁbrosis and complications
of atherosclerosis [29,113].
Several patients were compound heterozygotes for the H129P
(histidine to proline) missense mutation (which in vitro had 4.6%
of normal enzyme activity) and the common E8SJM1G>A allele1238 Journal of Hepatology 2013(genotype H129P/E8SJM1G>A). Three siblings with the
E8SJM1G>A/H129P genotype were diagnosed as adults (32, 44,
and <52 years) [26]. All three had signiﬁcant liver disease includ-
ing cirrhosis and esophageal varices, and one died of liver failure
at 56 years of age [26]. Since the publication, a second sibling
passed away, and the third received a liver transplant (personal
communication, Dr. C. Gasche, [26]). In contrast, a patient with
compound heterozygosity for H129R (histidine to arginine) and
a gene deletion, had onset at 18 months of age [57]. After publi-
cation, this patient also developed liver failure and received a
liver transplant at 9 years of age, four years after the case report
was published (personal communication Dr. V. McLin). These
patients illustrate the importance of both alleles and the protein
conformational alteration by the amino acid substitution in pre-
dicting patient’s severity. Of note, the CESD patients with the
T288I/T288I (in vivo the T288I protein had 3.6% of normal activ-
ity), and G342R/S289C genotypes both had a WD-like presenta-
tion, including infantile-onset, diarrhea, adrenal calciﬁcations
and failure to thrive. However, they had sufﬁcient residual LAL
activity to survive into the second or third decades of life, after
liver transplantation. The patient homozygous for T288I was liver
transplanted at 7 years of age [88,90]. The patient with the
G342R/S289C genotype survived to age 18 years, when liver fail-
ure led to liver transplantation, and subsequent demise (Table 3:
patient 54) [92]. The patients homozygous for H295Y (which had
2.9% of normal activity) also had infantile-onset CESD, requiring
liver transplantation at age 11 years, and two unrelated patients
with an E8SJM1G>A/c.323T>A and E8SJM1G>A/S344L
(c.967delAG >fs?338X) genotype, both had infantile-onset dis-
ease, but survived into their 30s at last follow-up [38,47,114].
These patients illustrate the early onset of disease manifestations,
which may rapidly progress in childhood or adolescence, or more
slowly progress into adulthood when liver failure leads to trans-
plantation or death.Treatment
Cholesterol reduction strategies
Only 35 (26%) of the reported patients were treated with HMG-
CoA reductase inhibitors for hyperlipidemia [13–
15,26,28,29,38,47,65–67,79,84,95,96,107,115–121]. The ﬁrst use
of statins to control the cholesterol synthesis abnormalities in
CESD was in a 9-year old girl with hepatomegaly, markedly ele-
vated serum total and LDL-cholesterol and decreased HDL-cho-
lesterol levels with massive CE accumulation, ﬁbrosis, and
cirrhosis on liver biopsy [107]. After 8 months of treatment with
5 mg/d of lovastatin, her dose was increased to 20 mg/d and the
patient’s plasma triglycerides, cholesterol and LDL-cholesterol
decreased, although the HDL-cholesterol level was not signiﬁ-
cantly increased. Since her liver and spleen volumes were
unchanged from baseline, the authors hypothesized that hepatic
CE production was increased in response to ApoB ﬂux-mediated
LDL receptor upregulation [107]. This hypothesis was subse-
quently supported by two later case reports that documented
favorable responses to simvastatin (0.28 mg/kg) and cholestyr-
amine after two years of treatment, which resulted in signiﬁcant
reductions in serum LDL-cholesterol, triglycerides and increased
HDL-cholesterol concentrations, with decreased liver volume,
and no changes in the transaminase levels, splenomegaly or adre-vol. 58 j 1230–1243
JOURNAL OF HEPATOLOGY
nal calciﬁcations. After 3 years of treatment, a liver biopsy
revealed increased ﬁbrosis with ensuing portal hypertension,
and after ﬁve years of treatment, the liver disease progression
necessitated liver transplantation [84,115].
Of the 35 patients taking statins, eight had no liver biopsy
ﬁndings reported, 15 had biopsy ﬁndings with ﬁbrosis, cirrhosis
or CESD-associated hepatopathology, but no long-term or
sequential follow-up data reported [18,29,47,53,60,65–67,89–
91,95,96,117,118,120–122]. The 12 remaining patients on
HMG-CoA reductase inhibitors had multiple liver biopsies, pro-
viding longitudinal data. There were no cases whose liver histol-
ogy improved, and all 12 patients had progressive liver disease
that was more advanced in subsequent biopsies, demonstrating
the progressive nature of liver disease in CESD. In fact, six
patients treated with HMG-CoA reductase inhibitors required
transplantation or died from liver failure
[15,26,28,38,47,48,62,79,84,115,116,119,123] (personal commu-
nication, Dr. C. Gasche, Dr. V. McLin). These ﬁndings emphasize
the lack of efﬁcacy of statins in ameliorating liver disease or pre-
venting its progression.
Liver transplantation
Liver transplantation was reported in nine patients who were ﬁve
to 14 years of age at transplantation [81,83–85,88,114,124,125].
At least three additional patients developed liver failure requiring
transplantation after the publication of their case reports, two of
whom subsequently died (Dr. C. Gasche, personal communication
[26]; Table 3: patients 36, 50, and 54). There is limited informa-
tion on the long-term follow-up for the majority of transplanted
patients, with several exceptions [80,81,83,112,126,127]. Six
liver-transplanted patients were followed from 10 months to
three years, reportedly without complications, despite one case
who had hepatocellular carcinoma that was found incidentally
in the removed liver. An additional patient who was transplanted
at ﬁve years of age had hyperbilirubinemia and elevated trans-
aminases suggestive of transplant rejection, and developed pro-
gressive, congestive heart failure [126]. Only two transplanted
patients had documented follow-up for over ﬁve years. One,
transplanted at 14 years of age, had a subsequent biliary infection
and obstruction requiring surgery. She developed end-stage renal
failure seven years post-transplant due to glomerular sclerosis
and atherosclerosis with extensive vascular lipid accumulation
and tubular atrophy, as well as interstitial ﬁbrosis, and required
chronic hemodialysis by 21 years of age. The lipid deposition in
the renal vascular system raised concern that the transplant
may have ameliorated only the liver disease, but not the systemic
lysosomal CE accumulation. The second patient for whom long-
term follow-up was reported had no renal involvement six years
after transplant [80,81,112].
Enzyme replacement therapy
ERT in CESDwas ﬁrst performed in cultured CESDﬁbroblasts using
a Pseudomonas-derived LAL (which was cross-linked to albumin
and/or conjugated to insulin or ApoB) [41]. These enzymeprepara-
tionswere incubated in themedia of the culturedCESDﬁbroblasts,
were taken up, and the intracellular enzyme degraded lysosomal-
ly-accumulated CEs. Subsequent efforts to develop ERT awaited
the generation and/or characterization of murine CESD models
and the puriﬁcation of LAL from various sources.Journal of Hepatology 2013Preclinical studies of ERT have been conducted in naturally-
occurring rats and in knockout mice with LAL deﬁciency
[128,129]. Rats with autosomal recessive LAL deﬁciency were
identiﬁed by Yoshida and Kuriyama in 1990 [128]. These rats
had 19% of wild-type hepatic LAL activity. Clinically, the rats
have hepatosplenomegaly, enlarged lymph nodes, and thickened,
dilated intestines. They have been characterized pathologically
and biochemically, and were found to closely mimic the liver dis-
ease pathology in humans, having microvesicular steatosis of the
hepatocytes and Kupffer cells, which progressed to ﬁbrosis and
micronodular cirrhosis. They do not have adrenal calciﬁcations.
More recently, a LIPA knockout mouse model was generated by
recombinant DNA techniques and characterized [122]. The mice
had no LAL enzyme activity or protein, and had massive hepatic
accumulation of CEs and triglycerides. In addition, the mice
developed the typical CESD hepatic, adrenal, and intestinal
pathology (i.e., hepatocyte, Kupffer cell, and other macrophage
and adrenocortical storage), survived to adulthood, and produced
progeny. These mice were used to evaluate ERT [42–44] and ade-
novirus-mediated gene therapy [130].
Preclinical trials of ERT were evaluated in the LIPA knockout
mice [42–44]. These studies evaluated the effectiveness of human
recombinant LAL expressed in Pichia pastoris [42], Chinese hamster
ovary (CHO); [43], or inNicotiana benthamiana (tobacco) cells [44].
Expression in yeast resulted in a recombinant human LAL (rhLAL)
with primarilymannose-terminated oligosaccharide chains, while
expression in CHO cells produced a human LAL with both man-
nose- and mannose-6-phosphate-terminated oligosaccharides
[42–44]. Ten intraperitoneal doses of each enzyme over 30 days
were administered. Themannose-terminated Pichia pastoris rhLAL
was delivered via themannose-receptor tomacrophages andmac-
rophage-derived cells in various organs. The CHO cell-produced
rhLAL had mannose-6-phophate terminated oligosaccharides and
clearedbothhepatocytes, Kupffer cells, andmacrophage-delivered
cells. The plant-derived rhLAL had mannose-receptor-dependent
uptake and, following 10 intravenous injections (every 3 days),
resulted in decreased hepatic CE and triglyceride concentrations,
and diminished foamymacrophages in the liver, spleen, and intes-
tinal villi [44]. When each enzyme was administered to double
knockout mice for LIPA and the macrophage mannose-receptor,
only theCHO-derived enzyme clearedbothhepatocyte andmacro-
phage cell lipid accumulations [43].
These preclinical studies provided the rationale for clinical tri-
als of ERT in WD and CESD with rhLAL produced in egg whites
[45]. A phase 1/2 randomized, double-blind, placebo-controlled,
open label, dose-escalation study was performed with rhLAL that
had both mannose- and mannose-6-phosphate oligosaccharides.
Three doses were evaluated (0.35, 1.0, and 3.0 mg/kg) weekly
for four weeks in CESD patients, followed by an extension study
with all participants receiving 1 mg/kg every other week. These
studies demonstrated the safety of the egg-white-derived rhLAL,
reduced the serum transaminase activities, and resulted in serum
LDL-cholesterol elevations evidencing the release of free choles-
terol from the accumulated CEs in lysosomes [45].
Disease management
Based on the clinical, pathological, and biochemical studies of the
patients reported in the literature, the following evaluations are
suggested to monitor disease progression. Annual laboratory
tests should include liver function tests (AST, ALT, prothrombinvol. 58 j 1230–1243 1239
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time, bilirubin), complete blood counts, chitotriosidase, (a macro-
phage inﬂammatory marker reported elevated in CESD; [29]), and
a lipid panel to assess dyslipidemia. Magnetic resonance imaging
should be performed periodically to determine liver and spleen
volumes and magnetic resonance spectroscopy can be used to
measure the hepatic fat fraction. Imaging studies, such as abdom-
inal ultrasound or esophagoduodenoscopy to monitor portal
hypertension and variceal bleeding, may be indicated. Cardiovas-
cular evaluations include an annual electrocardiogram and echo-
cardiogram, as well as carotid intima media thickness, and a
neurovascular evaluation for stroke risk should be considered.Discussion
Previously, there have been no prospective or retrospective natu-
ral history studies of CESD patients. Of the 135 CESD cases
reported in the literature, most were diagnosed incidentally by
the characteristic liver pathology, and/or conﬁrmed by deﬁcient
LAL enzyme activity or by LIPA gene analyses. All reported cases
had signiﬁcant liver disease characterized by microvesicular ste-
atosis that progresses to micronodular cirrhosis and liver failure.
Clinically, CESD has a variable age of onset, and is often unrec-
ognized, particularly in adults, until the unexplained hepatomeg-
aly, with or without splenomegaly, elevated transaminase
activities, and/or type IIb hyperlipoproteinemia lead to diagnostic
investigation. Typically, a liver biopsy will reveal the striking yel-
low-orange color, foamy lipid-laden hepatocytes and macro-
phages (Fig. 1A and B), and the pathognomonic lysosomal CE
crystals, best observed by ultrastructural examination (Fig. 1F).
However, awareness of this lysosomal storage disease is limited,
and many patients were originally missed clinically. The liver
biopsy may be misdiagnosed as NASH, NAFLD, or cryptogenic cir-
rhosis [4]. Diagnostic suspicion can be conﬁrmed by demonstrat-
ing the markedly deﬁcient LAL activity (Fig. 2) [109], or by LIPA
mutation analyses, which accurately detect both affected patients
and heterozygotes for this autosomal recessive disease.
Based on this review, affected children tend to have a severe
course that leads to early liver failure and transplantation.
Although liver transplantation has been effective in preventing
death from liver failure, extrahepatic organ involvement, even
in transplanted patients, resulted in signiﬁcant disease burden
and in some patients premature demise. Patients diagnosed later
in life tend to have a more attenuated course; however, there are
no long-term data on the morbidity and mortality of these
patients. The later-onset patients may be the most underdiag-
nosed cohort, since they often appear asymptomatic, other than
having type IIb hyperlipoproteinemia, until stroke, aneurysm,
aorto-coronary disease or premature sudden death from liver
failure lead to the diagnosis.
Given that ERT clinical trials for CESD are now underway, the
need for increased disease awareness is paramount. LAL deﬁ-
ciency should be included in the differential diagnosis for all
patients with elevated serum total cholesterol and LDL-choles-
terol who also may have mildly to moderately decreased HDL-
cholesterol, elevated transaminases and hepatomegaly. The
availability of non-invasive LAL enzyme and LIPA gene molecular
diagnoses can abrogate the need for a liver biopsy to conﬁrm the
CESD diagnosis. However, CESD should be suspected for any liver
biopsy that is orange-yellow in color, with microvesicular steato-
sis and/or micronodular cirrhosis. The CESD diagnosis can be1240 Journal of Hepatology 2013established by immunostaining for LAMP1, LAMP2, LIMP2 or
cathepsin D, or by demonstrating pathognomonic CE crystals or
their remnant clefts by electron microscopy. It is anticipated that
awareness of CESD by hepatologists, pathologists, cardiologists,
and neurologists will lead to greater detection of patients, partic-
ularly among adults, leading to improved management and
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